In a proposed pair of studies, the FDA will look at healthcare providers' and patients' responses to determine their ability to detect different…

Bayer’s $66 billion Monsanto takeover has plenty of critics. But thanks to an $8 billion R&D pledge, it has one key backer: U.S. President-elect Donald…

Even as the WHO said last year that the deadly Ebola outbreak was no longer an international emergency, vaccine experts continue to press officials to not let…

Astellas pulled the plug on a cell culture flu vaccine partnership with UMN Pharma after Japanese regulators stiff-armed its application for approval.

Sanofi and Regeneron asked a U.S. appeals court to let them continue selling their PCSK9 drug Praluent while a bitter patent dispute with Amgen continues.…

Several blockbusters are set for a nosedive this year as patent losses hit Novartis, Merck & Co., Bristol-Myers Squibb and other top pharmas.

Experts say the FDA's orphan drug system has been "hijacked" by drugmakers seeking protected profits on mass-market treatments.

The Supreme Court will take on a closely watched patent skirmish between Amgen and Novartis’ Sandoz that could determine timelines for future biosim launches.

Biogen has settled its Tecfidera patent fight with Forward Pharma for a whopping $1.25 billion in upfront cash, plus potential royalties, sending Forward'…